Back
CSTF2HGNC X-linkedmedRxivFunctional SNVNew mechanism

Inactivating mutations in polyadenylation factor CSTF2 disrupt intronic polyadenylation patterns and are associated with intellectual disability

Kainov Y, Foley PA, Igbokwe R, et al. — medRxiv 2026 · November 2026
Relevance score
6/10
Disease / domain
X-linked intellectual disability
Source
medRxiv
DOI 10.64898/2026.11.10.26367664

Variant / mechanism

CSTF2

Inactivating CSTF2 variants reducing intronic polyadenylation site usage in favour of distal 3'UTR sites

Summary

CSTF2, which encodes an RNA-binding subunit of the cleavage stimulation factor complex, had been linked to X-linked intellectual disability only through a single missense variant, p.Asp50Ala, which increases RNA binding. The authors report seven rare CSTF2 variants (missense, nonsense, splice-site and frameshift) in ten hemizygous male probands with intellectual disability, global developmental delay and/or autism spectrum disorder. Functional analysis of selected variants, using RNA sequencing and 3'-end-proximal sequencing in CSTF2-depleted cells, identified p.Phe19Leu, p.Gln543Ter and p.Leu555Ser as strongly impairing: they mainly reduce intronic polyadenylation site usage in favour of downstream sites in terminal 3'UTRs. The p.Asp50Ala variant produced the opposite pattern, with preferential activation of intronic sites, suggesting that both reduced and increased CSTF2 activity disrupt the balance of polyadenylation site usage and can cause a neurodevelopmental disorder.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Analysis

CSTF2 is not a new gene (first variant described in 2020 in Nucleic Acids Res), but this work moves it from an isolated observation to a series of ten patients with a supported loss-of-function mechanism. When interpreting the exome of a boy with a neurodevelopmental disorder, a truncating CSTF2 variant becomes a serious candidate. Preprint: segregation and variant origin are not detailed in the abstract, and only three variants are shown to be strongly impairing.

Analysis by Dr Thibaut Benquey

Why this score?

Impact 2/3Evidence 2/3Novelty 1/2Sample 1/1Publication 0/1

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 6/10

Keywords

intellectual disabilityneurodevelopmental disorderX-linkedpolyadenylationautism
Weekly report in your inbox

Every Wednesday · Annotated selection · Free · Unsubscribe anytime